Collectionner le produit
Détails du produit
Synonyms
Nucleocapsid protein, NP, Protein N
Source
SARS-CoV-2 Nucleocapsid protein, His Tag (NUN-C5221) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 419 (Accession # QHO62115.1).
Predicted N-terminus: Met 1
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 47.3 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 10 mM PB, 150 mM NaCl, pH7.4.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
SARS-CoV-2 Nucleocapsid protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 with a linear range of 0.1-3 ng/mL (QC tested).
Protocol
Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) with a linear range of 0.1-3 ng/mL (QC tested).
Protocol
Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 NP Antibody, Rabbit MAb (CLN27) with a linear range of 0.05-2 ng/mL (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Nucleocapsid proteins
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
2 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
